Related Experiment Video

Updated: Aug 1, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.5K

Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease

William Ackley1, Neera K Dahl2, Meyeon Park3

  • 1Department of Nephrology, University of Connecticut, Nephrology, Farmington, CT.

Advances in Kidney Disease and Health
|April 23, 2023
PubMed

Insights

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic kidney disorder. Tolvaptan is the only approved treatment targeting rapid progression, with other therapies also considered for ADPKD management.

Area of Science:

  • Nephrology
  • Genetics
  • Pharmacology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic kidney disorder.
  • It is the fourth leading cause of end-stage kidney disease (ESKD).
  • The pathogenesis of ADPKD is not fully understood, leading to significant morbidity beyond kidney disease.

Purpose of the Study:

  • To detail the use and prescription of tolvaptan for ADPKD.
  • To discuss other potential therapies for ADPKD treatment.
  • To provide an overview of current ADPKD management strategies.

Main Methods:

  • Review of current literature on ADPKD treatments.
  • Analysis of tolvaptan's mechanism of action and clinical application.
  • Discussion of emerging and supportive therapies for ADPKD.

Main Results:

  • Tolvaptan, approved in 2018, is the sole mechanism-specific therapy for individuals at risk of rapid ADPKD progression.
  • Risk assessment for rapid progression is a critical factor in treatment decisions.
  • Various therapeutic approaches, including tolvaptan and others, are considered for managing ADPKD patients.

Conclusions:

  • Tolvaptan represents a significant advancement in ADPKD management by targeting rapid progression.
  • Comprehensive treatment strategies involve risk assessment and consideration of multiple therapeutic options.
  • Further research into ADPKD pathogenesis may yield additional treatment targets.

Keywords:
ADPKDAquaresisGenetic kidney diseasesLiver cystsTolvaptan

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

9.8K
Evaluation of Zebrafish Kidney Function Using a Fluorescent Clearance Assay08:13

Evaluation of Zebrafish Kidney Function Using a Fluorescent Clearance Assay

Published on: February 20, 2015

13.3K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
57
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
11
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
32
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
49